FDA approves Avastin for platinum-resistant, recurrent ovarian cancer

the ONA take:

Roche has announced that the U.S. Food and Drug Administration (FDA) has approved Avastin (bevacizumab) for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with pacltiaxel, pegylated liposomal doxorubicin, or topotecan.

The drug is indicated for patients who have received no more than 2 prior chemotherapy regimens. The recommended dose of this indication is bevacizumab 10mg/kg every 2 weeks in combination with one of the above intravenous chemotherapy regimens, or bevacizumab 15mg/kg every 3 weeks in combination with topotecan.

The approval by the FDA is based upon the randomized, open-label, multicenter, phase 3 AURELIA trial, which investigated bevacizumab plus chemotherapy versus chemotherapy alone in 361 patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer that recurred within 6 months from the most recent treatment with platinum-based therapy.

Patients had a median age of 61 years. Median progression-free survival was 6.8 months and 3.4 months for chemotherapy plus bevacizumab and chemotherapy alone, respectively (P < 0.0001). Overall survival was 16.6 months and 13.3 months for chemotherapy plus bevacizumab and chemotherapy alone. This FDA approval is the sixth indication for Avastin.

FDA approves Avastin for platinum-resistant, recurrent ovarian cancer
Avastin (bevacizumab) approved for treatment of platinum-resistant recurrent epithelial ovarian cancer.

Cancer drug Avastin is already enjoying wide acceptance in Europe after it was approved for use earlier in the year. The same could happen in the United States soon as the Food and Drug Administration recently approved the use of Avastin as a treatment option alongside chemotherapy in battling platinum-resistant, recurrent ovarian cancer. Roche announced the approval Monday, based on results from a Phase III AURELIA study showing that using Avastin in combination with chemotherapy cut risks of worsening or death by up to 62 percent in women who have platinum-resistant, recurrent ovarian cancer compared to those who underwent chemotherapy alone.

"Avastin plus chemotherapy is the first new treatment option for women with this difficult-to-treat type of ovarian cancer in more than 15 years," said Roche Global Product Development Head and chief medical officer, Sandra Horning, M.D.

READ FULL ARTICLE From Techtimes
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs